GAIA-BT announced the results of its contract research with Cyron Therapeutics (led by CEO Sangsoon Yoon), a company specializing in antibody discovery and development. In follow-up experiments run by Cyron Therapeutics, a new antibody prototype developed with design from GAIA-Phil™, the agentic core of the K-GEM™ ecosystem, successfully recovered its full binding after unmasking.
The research was carried out under the research and development contract the two companies signed in June 2026 to advance Cyron’s “E-MASK TA-MUC1 ADC” platform, with GAIA-Phil™’s Optimization Agent applied to Cyron’s drug candidates. A masked antibody is designed to stay inactive until its mask is removed, and then bind its target as strongly as the original (parent) antibody. Cyron’s existing design masked well but recovered only part of its binding once unmasked.
- Analysis: GAIA-Phil™’s analysis, hypothesis and design agents reviewed five sequences supplied by Cyron, using structural and molecular dynamics (MD) analysis.
- Design: The agents reviewed design hypotheses and proposed candidate sequences.
- Validation: Cyron synthesized the candidates and ran function tests in its own wet lab.
In Cyron’s independent validation, the existing design (MsMP1-3-1a) recovered 48.8% binding after unmasking against 74.0% for the parent antibody at 10 µg/mL, and 30.2% against 62.0% at 1 µg/mL. The new prototype (H2) stayed suppressed while masked (18.7% at 20 µg/mL; 11.2% at 10 µg/mL). Once unmasked, it returned to the parent antibody’s level: 88.0% against 88.7% at 20 µg/mL, and 85.2% against 84.7% at 10 µg/mL.
Cyron plans further validation next, including monomer EC50, protection in sMUC1-positive serum, ADC internalization, and in vivo studies. These results come from early-stage laboratory research.
A word from Cyron Therapeutics:
Cyron Therapeutics CEO Sangsoon Yoon said, “We are pleased that our collaboration with GAIA-BT has produced positive results and look forward to our continued cooperation.”